Conventional anticancer therapeutics often suffer from lack of specificity, resulting in poor
therapeutic indexes and substantial toxicities to normal healthy tissues. Monoclonal …

With over 20 antibody‐drug conjugates in clinical trials as well as a recently FDA‐approved
drug, it is clear that this is becoming an important and viable approach for selectively …

Highlights•Antibody–drug conjugates represent an exciting new class of cancer
therapeutics.•ADCs comprise monoclonal antibodies that selectively deliver potent cytotoxic …

Antibody-drug conjugates are monoclonal antibodies attached to biologically active drugs
through chemical linkers that deliver and release cytotoxic agents at the tumor site, reducing …

Conventional cancer chemotherapy heavily relies on the use of cytotoxic agents, which
typically do not preferentially localize at the tumor site and cause toxicity to normal organs …

Significant progress has been made in the past few years in the area of antibody drug
conjugates (ADCs) for the selective delivery of cytotoxic drugs to tumors. Early work in this …

With the recent approvals of brentuximab vedotin (Adcetris; Seattle Genetics/Millennium
Pharmaceuticals) and ado-trastuzumab emtansine (Kadcyla (T-DM1); Roche/Genentech) …

Monoclonal antibodies have evolved from research tools to powerful therapeutics in the past
30 years. Clinical success rates of antibodies have exceeded expectations, resulting in …

Drug conjugates, including antibody-drug conjugates, are a step toward realizing Paul
Ehrlich's idea from over 100 years ago of a “magic bullet” for cancer treatment. Through …

One approach to improving activity of anticancer drugs is to conjugate them to antibodies
that recognize tumor-associated, cell-surface antigens. The antibody–drug conjugate …